Eurobio Oncologia
EndoPredict: Case study
Watch Prof. Untch’s Case Study
- 43 years old, premenopausal, pT1c, N0, G2, L0, V0, R0, ER 100%, HER2-, PR 100%, Ki67 15%, early-stage breast cancer patient
- Poll of other clinicians’ case opinions
- How her EndoPredict result supported a confident treatment decision
- Clinical validation of the test in this patient group
Get Clear Results
0
%
Risk of distant recurrence within 10 years
0
%
Absolute individualized chemotherapy benefit
0
%
5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone
Have Informed Conversations
EndoPredict results are simple to understand and straightforward to explain.
For this case, you could say:
- Your EndoPredict result indicates that your cancer is unlikely to come back in other parts of your body.
- This result takes into account both your tumor’s gene activity and clinical information, giving a personalized view of your situation.
- It suggests there is a 92% probability that your cancer will not return within the next 10 years.
- Chemotherapy could slightly improve this probability by about 2%, but for many patients, the small benefit may not justify the potential side effects.
Make Confident Decisions Knowing Her Result
- Comes from the most advanced, second-generation prognostic and predictive test1,2
- Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
- Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
- Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
- Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11
What it Meant for this Patient
Based on her clear EndoPredict result, the patient and her clinician decided to proceed without chemotherapy – avoiding unnecessary side effects while feeling confident in her favorable long-term outlook.
Riferimenti
- Sestak I. et al: Confronto delle prestazioni di 6 indicatori prognostici per il cancro al seno positivo al recettore degli estrogeni. Un'analisi secondaria di uno studio clinico randomizzato. JAMA Oncol. 2018
- Sestak I. et al: Previsione del beneficio della chemioterapia mediante EndoPredict in pazienti con carcinoma mammario sottoposte a terapia endocrina adiuvante più chemioterapia o a sola terapia endocrina. Breast Cancer Res Treat. 2019
- Filipits M. et al: Un nuovo predittore molecolare di recidiva a distanza nel cancro al seno ER-Positivo e HER2-Negativo aggiunge informazioni indipendenti ai fattori di rischio clinici convenzionali. Clin. Cancer Res. 2011
- Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
- Filipits M. et al: Previsione della recidiva a distanza utilizzando EndoPredict tra le donne con tumore al seno ER+, HER2- nodo- positivo e nodo-negativo trattate solo con terapia endocrina. Clin Cancer Res. 2019
- Constantinidou A. et al: Validazione clinica di EndoPredict in donne in pre-menopausa con tumore mammario primario ER-Positivo e HER2-Negativo. Clin. Cancer Res. 2022
- Buus R. et al: Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Klein, E. et al: Dati sull'esito a lungo termine utilizzando EndoPredict come biomarcatore di stratificazione del rischio e di decisione sulla chemioterapia nel carcinoma mammario precoce positivo ai recettori ormonali e HER2-negativo. Breast Cancer Res Treat. 2024
- Schmitt, W. D. e altri: Valutazione retrospettiva degli esiti in una coorte prospettica del mondo reale utilizzando EndoPredict: Risultati del registro Charité. SABCS 2022
- Vázquez-Juarez D. et al: Follow-up di una coorte prospettica di donne messicane in premenopausa con cancro al seno che hanno ricevuto un trattamento adiuvante guidato con il test EndoPredict. SABCS 2021
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Watch Prof. Untch’s Case Study
- 50 years old, postmenopausal, pT2, N1, G2, L0, V0, R0, ER 30/80%, PR 100/90%, Ki67 10%, lobular early-stage breast cancer patient
- Poll of other clinicians’ case opinions
- How her EndoPredict result changed the treatment decision
- Clinical validation of the test in this patient group
Get Clear Results
Based on her individualized risk score. See her full report
0
%
Risk of distant recurrence within 10 years
0
%
Absolute individualized chemotherapy benefit
0
%
5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone
Have Informed Conversations
EndoPredict results are simple to understand and straightforward to explain.
For this case, you could say:
- Your EndoPredict result shows that your cancer is at low-risk of coming back in other parts of your body.
- The result combines information from your tumor’s gene activity and clinical factors to give a clear picture of your situation.
- Based on this, there is a 91% chance your cancer will not return within 10 years.
- Adding chemotherapy could increase this chance by 3%, but the small potential benefit may not outweigh the possible side effects.
Make Confident Decisions Knowing Her Result
- Comes from the most advanced, second-generation prognostic and predictive test.1,2
- Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
- Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
- Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
- Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11
What it Meant for this Patient
Guided by her result, the patient and her clinician chose to continue treatment without chemotherapy, sparing her from potential side effects and giving them confidence in her treatment plan.
Riferimenti
- Sestak I. et al: Confronto delle prestazioni di 6 indicatori prognostici per il cancro al seno positivo al recettore degli estrogeni. Un'analisi secondaria di uno studio clinico randomizzato. JAMA Oncol. 2018
- Sestak I. et al: Previsione del beneficio della chemioterapia mediante EndoPredict in pazienti con carcinoma mammario sottoposte a terapia endocrina adiuvante più chemioterapia o a sola terapia endocrina. Breast Cancer Res Treat. 2019
- Filipits M. et al: Un nuovo predittore molecolare di recidiva a distanza nel cancro al seno ER-Positivo e HER2-Negativo aggiunge informazioni indipendenti ai fattori di rischio clinici convenzionali. Clin. Cancer Res. 2011
- Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
- Filipits M. et al: Previsione della recidiva a distanza utilizzando EndoPredict tra le donne con tumore al seno ER+, HER2- nodo- positivo e nodo-negativo trattate solo con terapia endocrina. Clin Cancer Res. 2019
- Constantinidou A. et al: Validazione clinica di EndoPredict in donne in pre-menopausa con tumore mammario primario ER-Positivo e HER2-Negativo. Clin. Cancer Res. 2022
- Buus R. et al: Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Klein, E. et al: Dati sull'esito a lungo termine utilizzando EndoPredict come biomarcatore di stratificazione del rischio e di decisione sulla chemioterapia nel carcinoma mammario precoce positivo ai recettori ormonali e HER2-negativo. Breast Cancer Res Treat. 2024
- Schmitt, W. D. e altri: Valutazione retrospettiva degli esiti in una coorte prospettica del mondo reale utilizzando EndoPredict: Risultati del registro Charité. SABCS 2022
- Vázquez-Juarez D. et al: Follow-up di una coorte prospettica di donne messicane in premenopausa con cancro al seno che hanno ricevuto un trattamento adiuvante guidato con il test EndoPredict. SABCS 2021
- Loibl S. et al: Carcinoma mammario precoce: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Watch Prof. Untch’s Case Study
- 68 years old, pT1b (9 mm), N0, G2, L0, V0, PN0, R0, ER 100%, PR 15%, Ki67 40% early-stage breast cancer patient
- Poll of other clinicians’ case opinions
- How her EndoPredict result changed the treatment decision
- Clinical validation of the test in this patient group
Get clear results
0
%
Risk of distant recurrence within 10 years
0
%
Absolute individualized chemotherapy benefit
0
%
5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone
Have Informed Conversations
EndoPredict results are simple to understand and straightforward to explain.
For this case, you could say:
- Your EndoPredict result shows a high-risk score.
- This means that, based on your tumor’s genes and other clinical factors, there is a 19% chance your cancer could come back within 10 years - about 1 in 5 patients.
- Chemotherapy can reduce this risk by around 8%, bringing it down to roughly 1 in 13, which may help improve your long-term outlook.
Make Confident Decisions Knowing Her Result
- Comes from the most advanced, second-generation prognostic and predictive test.1,2
- Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
- Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
- Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
- Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11
What it Meant for this Patient
Guided by her result, the patient and her clinician chose to continue treatment without chemotherapy, sparing her from potential side effects and giving them confidence in her treatment plan.
Riferimenti
- Sestak I. et al: Confronto delle prestazioni di 6 indicatori prognostici per il cancro al seno positivo al recettore degli estrogeni. Un'analisi secondaria di uno studio clinico randomizzato. JAMA Oncol. 2018
- Sestak I. et al: Previsione del beneficio della chemioterapia mediante EndoPredict in pazienti con carcinoma mammario sottoposte a terapia endocrina adiuvante più chemioterapia o a sola terapia endocrina. Breast Cancer Res Treat. 2019
- Filipits M. et al: Un nuovo predittore molecolare di recidiva a distanza nel cancro al seno ER-Positivo e HER2-Negativo aggiunge informazioni indipendenti ai fattori di rischio clinici convenzionali. Clin. Cancer Res. 2011
- Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
- Filipits M. et al: Previsione della recidiva a distanza utilizzando EndoPredict tra le donne con tumore al seno ER+, HER2- nodo- positivo e nodo-negativo trattate solo con terapia endocrina. Clin Cancer Res. 2019
- Constantinidou A. et al: Validazione clinica di EndoPredict in donne in pre-menopausa con tumore mammario primario ER-Positivo e HER2-Negativo. Clin. Cancer Res. 2022
- Buus R. et al: Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Klein, E. et al: Dati sull'esito a lungo termine utilizzando EndoPredict come biomarcatore di stratificazione del rischio e di decisione sulla chemioterapia nel carcinoma mammario precoce positivo ai recettori ormonali e HER2-negativo. Breast Cancer Res Treat. 2024
- Schmitt, W. D. e altri: Valutazione retrospettiva degli esiti in una coorte prospettica del mondo reale utilizzando EndoPredict: Risultati del registro Charité. SABCS 2022
- Vázquez-Juarez D. et al: Follow-up di una coorte prospettica di donne messicane in premenopausa con cancro al seno che hanno ricevuto un trattamento adiuvante guidato con il test EndoPredict. SABCS 2021
- Loibl S. et al: Carcinoma mammario precoce: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
